Literature DB >> 23152542

The C-terminus of CBFβ-SMMHC is required to induce embryonic hematopoietic defects and leukemogenesis.

Yasuhiko Kamikubo1, R Katherine Hyde, Ling Zhao, Lemlem Alemu, Cecilia Rivas, Lisa J Garrett, P Paul Liu.   

Abstract

The C-terminus of CBFβ-SMMHC, the fusion protein produced by a chromosome 16 inversion in acute myeloid leukemia subtype M4Eo, contains domains for self-multimerization and transcriptional repression, both of which have been proposed to be important for leukemogenesis by CBFβ-SMMHC. To test the role of the fusion protein's C-terminus in vivo, we generated knock-in mice expressing a C-terminally truncated CBFβ-SMMHC (CBFβ-SMMHCΔC95). Embryos with a single copy of CBFβ-SMMHCΔC95 were viable and showed no defects in hematopoiesis, whereas embryos homozygous for the CBFβ-SMMHCΔC95 allele had hematopoietic defects and died in mid-gestation, similar to embryos with a single-copy of the full-length CBFβ-SMMHC. Importantly, unlike mice expressing full-length CBFβ-SMMHC, none of the mice expressing CBFβ-SMMHCΔC95 developed leukemia, even after treatment with a mutagen, although some of the older mice developed a nontransplantable myeloproliferative disease. Our data indicate that the CBFβ-SMMHC's C-terminus is essential to induce embryonic hematopoietic defects and leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152542      PMCID: PMC3557645          DOI: 10.1182/blood-2012-06-434688

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.

Authors:  Tanawan Kummalue; Jianrong Lou; Alan D Friedman
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

2.  A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.

Authors:  Boet van Riel; Tibor Pakozdi; Rutger Brouwer; Rui Monteiro; Kapil Tuladhar; Vedran Franke; Jan Christian Bryne; Ruud Jorna; Erik-Jan Rijkers; Wilfred van Ijcken; Charlotte Andrieu-Soler; Jeroen Demmers; Roger Patient; Eric Soler; Boris Lenhard; Frank Grosveld
Journal:  Mol Cell Biol       Date:  2012-07-16       Impact factor: 4.272

3.  The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor.

Authors:  B Lutterbach; Y Hou; K L Durst; S W Hiebert
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

4.  Polyomavirus enhancer-binding protein 2/core binding factor/acute myeloid leukemia factors contribute to the cell type-specific activity of the CD11a integrin gene promoter.

Authors:  A Puig-Kröger; C López-Rodriguez; M Relloso; T Sánchez-Elsner; A Nueda; E Muñoz; C Bernabéu; A L Corbi
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

5.  Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11.

Authors:  Mondira Kundu; Amy Chen; Stacie Anderson; Martha Kirby; LiPing Xu; Lucio H Castilla; David Bodine; Pu Paul Liu
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

6.  RUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements.

Authors:  Amaya Puig-Kröger; Tilman Sanchez-Elsner; Natividad Ruiz; Enrique J Andreu; Felipe Prosper; Uffe B Jensen; Juana Gil; Paul Erickson; Harry Drabkin; Yoram Groner; Angel L Corbi
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

7.  Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia.

Authors:  P Liu; S A Tarlé; A Hajra; D F Claxton; P Marlton; M Freedman; M J Siciliano; F S Collins
Journal:  Science       Date:  1993-08-20       Impact factor: 47.728

8.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

9.  AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression.

Authors:  Florence Bernardin-Fried; Tanawan Kummalue; Suzanne Leijen; Michael I Collector; Katya Ravid; Alan D Friedman
Journal:  J Biol Chem       Date:  2004-01-27       Impact factor: 5.157

10.  The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.

Authors:  Kristie L Durst; Bart Lutterbach; Tanawan Kummalue; Alan D Friedman; Scott W Hiebert
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

View more
  11 in total

1.  Rare germline alterations in cancer-related genes associated with the risk of multiple primary tumor development.

Authors:  Rolando A R Villacis; Tatiane R Basso; Luisa M Canto; Maísa Pinheiro; Karina M Santiago; Juliana Giacomazzi; Cláudia A A de Paula; Dirce M Carraro; Patrícia Ashton-Prolla; Maria I Achatz; Silvia R Rogatto
Journal:  J Mol Med (Berl)       Date:  2017-01-16       Impact factor: 4.599

2.  HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.

Authors:  Jing Qi; Sandeep Singh; Wei-Kai Hua; Qi Cai; Shi-Wei Chao; Ling Li; Hongjun Liu; Yinwei Ho; Tinisha McDonald; Allen Lin; Guido Marcucci; Ravi Bhatia; Wei-Jan Huang; Chung-I Chang; Ya-Huei Kuo
Journal:  Cell Stem Cell       Date:  2015-09-18       Impact factor: 24.633

3.  RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.

Authors:  Tao Zhen; Yaqiang Cao; Gang Ren; Ling Zhao; R Katherine Hyde; Guadalupe Lopez; Dechun Feng; Lemlem Alemu; Keji Zhao; P Paul Liu
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

4.  Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11.

Authors:  Tao Zhen; Erika M Kwon; Ling Zhao; Jingmei Hsu; R Katherine Hyde; Ying Lu; Lemlem Alemu; Nancy A Speck; P Paul Liu
Journal:  Blood       Date:  2017-10-10       Impact factor: 22.113

Review 5.  Emerging therapies for inv(16) AML.

Authors:  Sridevi Surapally; Daniel G Tenen; John A Pulikkan
Journal:  Blood       Date:  2021-05-13       Impact factor: 22.113

6.  Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice.

Authors:  R K Hyde; L Zhao; L Alemu; P P Liu
Journal:  Leukemia       Date:  2015-03-06       Impact factor: 11.528

7.  The C-terminal multimerization domain is essential for leukemia development by CBFβ-SMMHC in a mouse knockin model.

Authors:  L Zhao; H Alkadi; E M Kwon; T Zhen; J Lichtenberg; L Alemu; J Cheng; A D Friedman; P P Liu
Journal:  Leukemia       Date:  2017-08-18       Impact factor: 11.528

Review 8.  Genetic compensation of RUNX family transcription factors in leukemia.

Authors:  Yasuhiko Kamikubo
Journal:  Cancer Sci       Date:  2018-08       Impact factor: 6.716

9.  CHD7 and Runx1 interaction provides a braking mechanism for hematopoietic differentiation.

Authors:  Jingmei Hsu; Hsuan-Ting Huang; Chung-Tsai Lee; Avik Choudhuri; Nicola K Wilson; Brian J Abraham; Victoria Moignard; Iwo Kucinski; Shuqian Yu; R Katherine Hyde; Joanna Tober; Xiongwei Cai; Yan Li; Yalin Guo; Song Yang; Michael Superdock; Eirini Trompouki; Fernando J Calero-Nieto; Alireza Ghamari; Jing Jiang; Peng Gao; Long Gao; Vy Nguyen; Anne L Robertson; Ellen M Durand; Katie L Kathrein; Iannis Aifantis; Scott A Gerber; Wei Tong; Kai Tan; Alan B Cantor; Yi Zhou; P Paul Liu; Richard A Young; Berthold Göttgens; Nancy A Speck; Leonard I Zon
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-03       Impact factor: 12.779

Review 10.  Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.

Authors:  Lisa Richter; Yiqian Wang; R Katherine Hyde
Journal:  Oncotarget       Date:  2016-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.